Mega funding deals recently returned to Chinese bioventures developing small molecule drugs, as investors seemingly reignited their enthusiasm for such companies. Reistone Biopharma Company Limited ,
BridgeBio Pharma, Inc. employs a business model of acquiring rights to or partnering with academic and institutional research in monogenic diseases and genetic cancer indications, often forming singl